What does this company do and how does it make money?

Regeneron generates revenue primarily through drug partnerships rather than direct product sales, with collaborations accounting for 51.1% of revenue. This partnership-dependent model concentrates risk but allows massive R&D investment at 41.9% of revenue while maintaining 22.7% operating margins.

Five legendary investment frameworks analyzed this company.

Mauboussin sees biotech optionality at utility prices while Lynch sees Con Edison growth at Amazon multiples—but it's the 20-quarter insider selling streak versus 86.6% institutional ownership that reveals the real bet on Regeneron's future. Tap any framework below to explore their complete analysis and discover where they see opportunity or risk.

How much cash does it generate and where does it go?

Regeneron allocates more to R&D than it generates in operating cash flow—138.9% in Q4'25—while simultaneously returning 65.3% through buybacks and dividends. This aggressive dual strategy of investing and returning capital works only because of strong underlying cash generation and a net cash position.

Is the business getting stronger or weaker?

The business shows alarming deterioration in capital efficiency, with ROIC plummeting from 14.96% to 1.97% over four years while revenue growth stalled at 1%. Gross margins remain fortress-like at 84.9%, but the company now destroys value with ROIC below its 5.94% cost of capital.

What could go wrong and has it survived trouble before?

Regeneron faces dual risks: extreme partnership dependence with 51.1% of revenue from collaborations and consistent insider selling for five years straight. The company demonstrated fragility during the 2022 rate shock when revenue plunged 42.3%, revealing high operating leverage that amplifies downturns.

When insiders sell for 20 consecutive quarters while institutions boost ownership to 86.6%, someone is profoundly wrong about Regeneron's future.

Is the stock priced for perfection, fair value, or pessimism?

At 23.5x earnings with a 1.06% yield versus 4.33% treasuries, Regeneron trades at a biotech premium despite minimal growth expectations of 0.91% implied by reverse DCF. The 61.3% discount to DCF value and underwater buybacks suggest the market has already priced in significant disappointment.